Pharmaceuticals

MSI-H And dMMR Industry Insights: Market Forecast to 2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The MSI-H And dMMR Market Size Likely To Evolve From 2025 Through 2034?

The MSI-H and dMMR market size has experienced significant expansion over recent years. It is anticipated to increase from $6.15 billion in 2024 to $7.57 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 23.0%. The growth observed in previous periods can be linked to a heightened incidence of colorectal and endometrial cancers, the broader implementation of genetic screening programs, an increasing clinical acceptance of MSI testing, growing awareness concerning hereditary cancer syndromes, and an uptick in the adoption of liquid biopsy.

The MSI-H and dMMR market size is projected to experience substantial growth in the upcoming years, with its value anticipated to reach “$17.26 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 22.9%. This expansion during the forecast period can be attributed to several factors, including an increasing demand for personalized cancer therapies, the broadening applications of next-generation sequencing, rising healthcare expenditure in oncology, a growing number of clinical trials for immune checkpoint inhibitors, and supportive regulatory frameworks for companion diagnostics. Major trends expected in the forecast period involve the integration of artificial intelligence into diagnostic workflows, collaborations between pharmaceutical and diagnostic companies, the development of multiplex biomarker panels, continuous advancements in immunotherapy, and a noticeable shift toward pan-cancer biomarker testing.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

Which Drivers Are Supporting Growth Of The MSI-H And dMMR Market?

The expanding incidence of cancer is anticipated to fuel the progress of the MSI-H and dMMR market moving forward. Cancer encompasses a range of illnesses marked by the unrestrained proliferation and dissemination of atypical cells within the body. The increasing occurrence of cancer is mainly attributed to aging demographics, as the probability of developing cancer rises considerably with age due to the accumulated impact of genetic alterations and prolonged exposure to risk factors. MSI-H and dMMR are employed in oncology to identify tumors exhibiting elevated mutation rates resulting from deficiencies in DNA repair pathways. These indicators aid in directing immunotherapy choices, given that such tumors often show a better response to immune checkpoint inhibitors, and they also offer insights into patient outlook and potential inherited conditions. For example, as reported by the American Cancer Society, a US-based non-profit organization, in January 2024, the United States recorded an estimated 1,958,310 new cancer cases and 609,820 cancer-related deaths in 2023. These figures are projected to climb in 2024, with around 2,001,140 new cancer cases and 611,720 deaths expected, underscoring a continuous upward trend in cancer incidence and mortality. Consequently, the increasing prevalence of cancer is propelling the expansion of the MSI-H and dMMR market.

What Are The Major Segments Identified In The MSI-H And dMMR Market?

The msi-h and dmmr market covered in this report is segmented –

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy

2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications

3) By Stage: Early Stages, Advanced Stages

4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors

2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

What Are The Major Trends Driving The Growth Of The MSI-H And dMMR Market?

Major companies operating in the MSI-H and dMMR market are focusing on developing innovative treatments, such as combination therapy, to enhance treatment efficacy and improve patient outcomes. Combination therapy for MSI-H and dMMR cancers involves utilizing two or more treatment modalities, frequently immunotherapy agents such as checkpoint inhibitors or combining immunotherapy with chemotherapy, targeted therapy, or radiation. This approach aims to improve treatment response, overcome resistance, and extend survival outcomes in patients with tumors exhibiting high microsatellite instability or deficient mismatch repair. For instance, in April 2025, Bristol-Myers Squibb Company, a US-based pharmaceutical company, received United States Food and Drug Administration (FDA) approval for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for metastatic colorectal cancer (mCRC) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) features, further advancing treatment options for this challenging cancer subtype. This approval signifies a substantial milestone in the treatment of MSI-H and dMMR cancers, as it provides a new, effective therapeutic option that targets multiple pathways to improve patient survival and response rates, addressing the unmet medical needs in this patient population.

Which Major Firms Are Strengthening Their Position In The MSI-H And dMMR Industry?

Major companies operating in the MSI-H and dMMR market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The MSI-H And dMMR Market?

North America was the largest region in the MSI-H and dMMR market in 2024. The regions covered in the MSI-H and dMMR market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The MSI-H And dMMR Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24324&type=smp

Browse Through More Reports Similar to the Global MSI-H And dMMR Market 2025, By The Business Research Company

Dna And Gene Chip Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dna-and-gene-chip-global-market-report

Dna Based Skin Care Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dna-based-skin-care-products-global-market-report

Dna Digital Data Storage Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dna-digital-data-storage-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795